ANIP ANI Pharmaceuticals Dashboard

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

Company profile

Ticker

ANIP

Exchange

NASDAQ

Website

www.anipharmaceuticals.com

CEO

Patrick Walsh

Incorporated

Delaware

Location

Minnesota

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

Former names

BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC

SEC CIK

0001023024

Corporate docs

Articles of Incorporation & Bylaws

IRS number

582301143

ANIP stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

ANI Pharmaceuticals Announces Refiling Of Cortrophin sNDA With FDA

6 Jul 21

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company has re-filed its supplemental new drug application ("sNDA") for Cortrophin® Gel

Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $60

10 May 21

Raymond James analyst Elliot Wilbur maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Outperform and raises the price target from $40 to $60.

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs

7 May 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)

ANI Pharmaceuticals Q1 EPS $1.04 Beats $0.71 Estimate, Sales $54.50M Beat $46.80M Estimate

7 May 21

Earnings Scheduled For May 7, 2021

7 May 21

Press releases

Pro users get this 30m faster

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

22 Jul 21

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021. Nikhil Lalwani, President and Chief

ANI Pharmaceuticals Announces Refiling of Cortrophin sNDA with FDA

6 Jul 21

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company has re-filed its supplemental new drug application ("sNDA") for Cortrophin® Gel with the U.S. Food and Drug

ANI Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference 2021

15 Jun 21

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Raymond James Human Health

ANI Pharmaceuticals Announces Details of 2021 Virtual Annual Meeting of Stockholders

1 Jun 21

ANI Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

27 May 21

Calendar

7 May 21

29 Jul 21

31 Dec 21

Financial summary

Financial statements Chart ANIP financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	30.07M	30.07M	30.07M	30.07M	30.07M	30.07M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	(positive/no burn)	859.5K	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	n/a	3.4M	n/a	n/a
Cash remaining	n/a	n/a	n/a	26.67M	n/a	n/a
Runway (months of cash)	n/a	n/a	n/a	31.0	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

ANIP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
12 Apr 21	Carey Stephen P.	Common Stock	Payment of exercise	Dispose F	No	No	31.86	3,042	96.92K	112,500
12 Apr 21	Marken James G.	Common Stock	Payment of exercise	Dispose F	No	No	31.86	1,878	59.83K	114,321
6 Apr 21	Carey Stephen P.	Common Stock	Payment of exercise	Dispose F	No	No	33.69	612	20.62K	115,542
6 Apr 21	Marken James G.	Common Stock	Payment of exercise	Dispose F	No	No	33.69	337	11.35K	116,199
29 Mar 21	Schrepfer Robert W	Common Stock	Payment of exercise	Dispose F	No	No	32.68	5,566	181.9K	87,477

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

ANIP institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Sun Pharmaceutical Industries • Evoke Pharma • Perrigo • Mylan II B.V. • Amneal Pharmaceuticals

Management Discussion

In July 2020, we acquired an ANDA and certain related inventories from a private company for total consideration of $4.3 million. The transaction was funded using cash on hand.
In May 2020, we entered into an agreement with a private company to purchase an ANDA and API for one currently marketed generic drug product and certain API for $0.2 million. The transaction was funded using cash on hand.
In January 2020, we completed the acquisition of the U.S. portfolio of 23 generic products and API and finished goods related to certain of those products from Amerigen Pharmaceuticals, Ltd. ("Amerigen") for a purchase consideration of $56.8 million and up to $25.0 million in contingent payments over the next three years. The product portfolio at the time of the acquisition included ten commercial products, three approved products with launches pending, four filed products and four in-development products as well as a license to commercialize two approved products. The transaction was funded using cash on hand and $15.0 million in borrowings under our $75.0 million Revolver.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: affiliate, Aid, Ampersand, answer, anticompetitive, antitrust, ApexiCon, assumption, attention, aware, Azurity, Baltimore, behavior, beneficial, biopharmaceutical, Bird, built, Bystolic, CDMO, Chairman, Christopher, Circuit, clear, CMS, Concurrently, connection, consummate, consummated, consummation, contemplated, corrupt, Cream, creative, customary, CVS, damage, deadline, default, defect, devote, diminish, Diphenoxylate, disagreement, discover, diverted, empowered, enhance, enhanced, ER, escrow, established, expertise, explore, export, fail, favorable, Fe, Forest, frame, fulfill, Glenmark, grew, grown, GTM, Gutwerg, Hetero, Hightower, identical, imposition, inability, indemnification, indemnifying, India, Indian, innovating, innovative, instability, Investor, issuable, ITA, Judicial, Kroger, leadership, leave, led, liable, light, LJL, lost, Lotion, Maryland, Medicare, merit, motion, moved, multiplied, Mutz, nonfinancial, North, Novitium, Ointment, oncology, oncolytic, Ori, OXISTAT, Pandel, Paragraph, partner, Partnership, pendency, perception, Pfizer, PIPE, placement, political, power, preemption, preferred, prejudice, programmatic, prospective, purposeful, pursuit, rare, recovered, remand, repatriation, replead, reputation, requisite, responsible, Rite, Rule, rupee, Sandoz, Santa, satisfaction, social, staffing, steady, steroid, stipulated, stockholder, strategic, sudden, suffer, terrorism, therewith, Torrent, training, transportation, unique, unrest, VEREGEN, version, voting, waived, Walgreen, Watson, York

Removed: achievement, acute, add, addressed, adjunct, adult, agent, aging, alter, amending, amendment, Amphetamine, antipsychotic, Arthur, atypical, bacteria, BAS, basket, bladder, bond, buy, Carey, ceased, CEO, charge, clarified, clarifying, collective, constipation, context, continuation, contrary, cumulative, declared, deduction, delinquent, demand, departure, diarrhea, diet, disorder, dispose, disqualifying, disruption, diversify, dL, economy, effort, eliminate, Ethyl, evidence, executing, extend, fourth, Glycol, Guide, hypertriglyceridemia, impacting, Impax, imposed, incontinence, increasing, initial, initiate, irrevocably, jiroveci, lack, launched, lead, long, Marken, matured, media, mg, Mixed, mL, modification, modify, monotherapy, mood, NEO, obtained, occasional, occurred, overactive, owed, package, participant, past, Penicillamine, PII, pneumonia, Polyethylene, prepayment, prevention, priority, proven, Przybyl, refinancing, reflective, repurchase, retain, Robert, schizoaffective, schizophrenia, Schrepfer, spread, Stephen, strongly, subset, Sulfamethoxazole, sum, susceptible, suspected, suspend, Suspension, Tartrate, Teva, titled, Tolterodine, Topic, tract, travel, traveler, treatment, triglyceride, Trimethoprim, type, unbilled, uncollectible, unexercised, unprecedented, unsecured, urge, urgency, urinary, USA, USP, vested, World, written

From filing 10-Q 2021 Q1